206 related articles for article (PubMed ID: 37446202)
1. Using Human 'Personalized' Cybrids to Identify Drugs/Agents That Can Regulate Chronic Lymphoblastic Leukemia Mitochondrial Dysfunction.
Singh L; Atilano S; Chwa M; Singh MK; Ozgul M; Nesburn A; Kenney MC
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446202
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of risuteganib and bevacizumab on AMD cybrid cells.
Schneider K; Chwa M; Atilano SR; Shao Z; Park J; Karageozian H; Karageozian V; Kenney MC
Exp Eye Res; 2021 Feb; 203():108287. PubMed ID: 33075294
[TBL] [Abstract][Full Text] [Related]
3. Impacts of Bacteriostatic and Bactericidal Antibiotics on the Mitochondria of the Age-Related Macular Degeneration Cybrid Cell Lines.
Salimiaghdam N; Singh L; Singh MK; Chwa M; Atilano SR; Mohtashami Z; Nesburn AB; Kuppermann BD; Lu SY; Kenney MC
Biomolecules; 2022 May; 12(5):. PubMed ID: 35625603
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitochondria target drugs.
Rodrigo R; Mendis N; Ibrahim M; Ma C; Kreinin E; Roma A; Berg S; Blay J; Spagnuolo PA
Autophagy; 2019 May; 15(5):900-907. PubMed ID: 30563411
[TBL] [Abstract][Full Text] [Related]
5. Potential Therapeutic Functions of PU-91 and Quercetin in Personalized Cybrids Derived from Patients with Age-Related Macular Degeneration, Keratoconus, and Glaucoma.
Salimiaghdam N; Singh L; Singh MK; Chwa M; Atilano S; Mohtashami Z; Nesburn A; Kuppermann BD; Kenney MC
Antioxidants (Basel); 2023 Jun; 12(7):. PubMed ID: 37507866
[TBL] [Abstract][Full Text] [Related]
6. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
Prinz C; Vasyutina E; Lohmann G; Schrader A; Romanski S; Hirschhäuser C; Mayer P; Frias C; Herling CD; Hallek M; Schmalz HG; Prokop A; Mougiakakos D; Herling M
Mol Cancer; 2015 Jun; 14():114. PubMed ID: 26041471
[TBL] [Abstract][Full Text] [Related]
7. Selective toxicity of persian gulf sea cucumber holothuria parva on human chronic lymphocytic leukemia b lymphocytes by direct mitochondrial targeting.
Salimi A; Motallebi A; Ayatollahi M; Seydi E; Mohseni AR; Nazemi M; Pourahmad J
Environ Toxicol; 2017 Apr; 32(4):1158-1169. PubMed ID: 27404045
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluoroquinolones and tetracyclines on mitochondria of human retinal MIO-M1 cells.
Salimiaghdam N; Singh L; Schneider K; Chwa M; Atilano SR; Nalbandian A; Limb GA; Kenney MC
Exp Eye Res; 2022 Jan; 214():108857. PubMed ID: 34856207
[TBL] [Abstract][Full Text] [Related]
9. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia.
Prezma T; Shteinfer A; Admoni L; Raviv Z; Sela I; Levi I; Shoshan-Barmatz V
Cell Death Dis; 2013 Sep; 4(9):e809. PubMed ID: 24052077
[TBL] [Abstract][Full Text] [Related]
10. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
[TBL] [Abstract][Full Text] [Related]
11. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
12. Differential mitochondrial and cellular responses between H vs. J mtDNA haplogroup-containing human RPE transmitochondrial cybrid cells.
Panvini AR; Gvritishvili A; Galvan H; Nashine S; Atilano SR; Kenney MC; Tombran-Tink J
Exp Eye Res; 2022 Jun; 219():109013. PubMed ID: 35283109
[TBL] [Abstract][Full Text] [Related]
13. Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia.
Darwiche W; Gomila C; Ouled-Haddou H; Naudot M; Doualle C; Morel P; Nguyen-Khac F; Garçon L; Marolleau JP; Ghamlouch H
J Exp Clin Cancer Res; 2020 Oct; 39(1):228. PubMed ID: 33115525
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial-dependent apoptosis in Huntington's disease human cybrids.
Ferreira IL; Nascimento MV; Ribeiro M; Almeida S; Cardoso SM; Grazina M; Pratas J; Santos MJ; Januário C; Oliveira CR; Rego AC
Exp Neurol; 2010 Apr; 222(2):243-55. PubMed ID: 20079354
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia.
Jitschin R; Hofmann AD; Bruns H; Giessl A; Bricks J; Berger J; Saul D; Eckart MJ; Mackensen A; Mougiakakos D
Blood; 2014 Apr; 123(17):2663-72. PubMed ID: 24553174
[TBL] [Abstract][Full Text] [Related]
16. Decreased reactive oxygen species production in cells with mitochondrial haplogroups associated with longevity.
Chen A; Raule N; Chomyn A; Attardi G
PLoS One; 2012; 7(10):e46473. PubMed ID: 23144696
[TBL] [Abstract][Full Text] [Related]
17. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Vaisitti T; Gaudino F; Ouk S; Moscvin M; Vitale N; Serra S; Arruga F; Zakrzewski JL; Liou HC; Allan JN; Furman RR; Deaglio S
Haematologica; 2017 Nov; 102(11):1878-1889. PubMed ID: 28860341
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
19. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
20. Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria.
Salimi A; Roudkenar MH; Sadeghi L; Mohseni A; Seydi E; Pirahmadi N; Pourahmad J
Redox Biol; 2015 Dec; 6():461-471. PubMed ID: 26418626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
